Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the present application:

1. (Original) A pharmaceutical composition comprising a compound having the following formula (I):



wherein:

(a) X is CH or N;

(b) R_1 is hydrogen, alkyl, aralky, heteroaralkyl, alkenyl, aralkenyl, heteroaralkenyl, aryl, or heteroaryl;

(c) R_2 is hydrogen, alkyl, aralky, aryl, or heteroaryl;

(d) $R_{2'}$ is hydrogen unless R_2 is methyl, in which case $R_{2'}$ is also methyl;

(e) R_3 has the following formula (III):



wherein:

(i) R_4 is hydrogen, alkyl, halo, hydroxy, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, or hydroxymethyl;

(ii) R_5 is hydrogen, alkyl, halo, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, amino, aminocarbonyl, aminosulfonyl, or hydroxymethyl;

(iii) R_6 is alkyl, halo, alkoxy, perfluoroalkyl, perfluoroalkoxy, or nitro;

(iv) R_4 and R_5 when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;

(v) R_5 and R_6 when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;

(f) L is selected from the group consisting of $-(CH_2)_m-$, where m is an integer from 1 to 6, and an alkyl substituted hydrocarbyl moiety of the formula (IV):



wherein:

(i) n is 0, 1 or 2;

(ii) R7 and R8 are hydrogen, methyl or ethyl;

(iii) R9 and R9' are both hydrogen, methyl or ethyl;

(iv) if n is 1 and R7 or R8 is methyl or ethyl, then R9 and R9' are hydrogen;

(v) if n is 1 and R7 and R8 are hydrogen, then R9 and R9' are methyl or ethyl; and

(vi) if n is 2, then R9 and R9' are hydrogen and one or both of R7 and R8 are methyl or ethyl.

and pharmaceutically acceptable salts and esters thereof.

2. (Original) The pharmaceutical composition of claim 1, wherein R_2 and $R_{2'}$, are both hydrogen.

3. (Original) The pharmaceutical composition of claim 1, wherein R_4 is selected from the group consisting of hydrogen, halo, and alkoxy.

4. (Original) The pharmaceutical composition of claim 1, wherein R_5 is selected from the group consisting of hydrogen, alkyl, halo, alkoxy, and perfluoroalkyl;

5. (Original) The pharmaceutical composition of claim 1, wherein R_6 is selected from the group consisting of alkyl, halo, alkoxy, and perfluoroalkyl.

6. (Original) The pharmaceutical composition of claim 1, wherein R_4 and R_5 when taken together form a naphthalene ring; and

7. (Original) The pharmaceutical composition of claim 1, wherein R_5 and R_6 when taken together are selected from the group consisting of a methylenedioxy group and an ethylenedioxy group.

8. (Original) The pharmaceutical composition of claim 1, wherein L is an alkyl substituted hydrocarbyl moiety of formula (IV).

9. (Original) The pharmaceutical composition of claim 1, comprising a pharmaceutically acceptable excipient.

10. (Original) A method of treating a psychiatric or neurological condition, comprising the step of administering a therapeutic dose of the pharmaceutical composition of claim 1 to a patient in need thereof.

11. (Original) The method of claim 10, wherein the therapeutic dose is administered by an administrative route selected from the group consisting of intravenous infusion, oral, topical, intraperitoneal, intravesical, transdermal, nasal, rectal, vaginal, intramuscular, intradermal, subcutaneous and intrathecal routes.

12. (Original) The method of claim 10, wherein the therapeutic dose is in the range of 0.0001 mg/kg to 60 mg/kg.

13. (Original) The method of claim 10, wherein the condition being treated is a psychiatric condition.

14. (Original) The method of claim 10, wherein the condition being treated is pain.

15. (Original) The method of claim 10, wherein the condition being treated is emesis.

16. (Original) The method of claim 10, wherein the condition being treated is neurodegeneration.

Claims 17-18 (canceled).

19. (New) The pharmaceutical composition of claim 1, wherein the compound is selected from the group consisting of:
1-{4-[4-(4-Fluorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;
1-{3-[4-(3,4-Dichlorophenyl)piperazin-1-yl]propyl}-1,5,6,7-tetrahydroindol-4-one;
1-{4-[4-(2,4-Dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;
1-{4-[4-(3-Chloro-4-fluorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;
1-{4-[4-(4-Bromophenyl)piperazine-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one; and
1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one

20. (New) The pharmaceutical composition of claim 19, wherein the compound is 1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one.

21. (New) The method of claim 10, wherein the pharmaceutical composition comprises 1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one.